Applications of Succinimido (S)-2-[(Tert-Butoxycarbonyl)Amino]Propionate in Industrial Manufacturing

As a direct manufacturer specialized in advanced chemical intermediates, we ensure that Succinimido (S)-2-[(Tert-Butoxycarbonyl)Amino]Propionate meets the strict purity, consistency, and compliance requirements of end-user industries. This compound plays critical roles in high-value downstream industries, particularly peptide synthesis, protected amino acid manufacture, active pharmaceutical ingredient (API) development, and custom fine chemicals production.

1. Peptide Synthesis Intermediates

Leading peptide manufacturers use this protected amino acid derivative as a core building block for solid-phase and solution-phase peptide synthesis. Its tert-butoxycarbonyl (Boc) protection provides controlled reactivity, essential for preventing side reactions during peptide chain assembly. The material's lot-to-lot purity minimizes sequence errors and optimizes coupling efficiency in pharmaceutical-grade peptide manufacturing, where regulatory oversight is strict.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• European Pharmacopoeia (Ph. Eur.) relevant monographs for peptide synthesis
• US FDA 21 CFR Part 211 (Current Good Manufacturing Practice for Finished Pharmaceuticals)
• ISO 9001:2015 Quality Management System in chemical production

Typical usage ratio

• Used at 1:1 molar ratio with other amino acid derivatives in peptide coupling protocols; ratio adjustments depend on specific peptide sequence and chain length
• Applied at up to 2 equivalents in cases of sterically hindered sequences
• Purity requirements typically ≥98% (HPLC)

Downstream process integration

• Deployed during initial chain initiation and elongation steps on resin (solid-phase)
• Protected moiety removed via controlled acidolysis after assembly
• Employed in batch and continuous peptide synthesis reactors
• Integrated with in-process QC (HPLC, MS) for each synthetic stage

Final product types

• Therapeutic peptides (GLP-1 agonists, vasopressin analogs, somatostatin derivatives)
• Cosmeceutical bioactive peptides
• Peptidomimetics and peptide libraries
• Diagnostic reagents and affinity ligands

2. API Precursor for Chiral Drug Synthesis

Chiral pharmaceutical API manufacturers employ (S)-2-[(Tert-Butoxycarbonyl)Amino]Propionate as a chiral precursor in the synthesis of alpha-amino acid-based drug substances. The protected group enhances selectivity in asymmetric synthesis and enables precise downstream functionalization for therapeutic molecule production. This raw material supports GMP-compliant manufacturing and downstream purification to meet regulatory specifications.

Industry compliance standards

• ICH Q7 and Q11 (Development and Manufacture of Drug Substances)
• US Pharmacopeia (USP-NF) and related monographs for APIs and intermediates
• EU GMP Annex 8 (Sampling of Starting and Packaging Materials)
• PIC/S Guide to GMP for Pharmaceutical Products

Typical usage ratio

• Used in stepwise reactions at 0.8–1.2 equivalents, adjusted for desired optical purity and downstream synthetic yield
• Batch-wise scale from grams to multi-kilogram volumes depending on API project stage
• Impurity limits typically <0.2% to comply with final API requirements

Downstream process integration

• Enters synthesis at chiral center formation or resolution step
• Boc group retained during early transformations, often removed prior to final API crystallization
• Integrated with chiral HPLC monitoring and intermediate isolation steps
• Used in both laboratory-scale route development and industrial-scale commercial batches

Final product types

• Chiral pharmaceutical active ingredients (antihypertensives, antineoplastics, antivirals)
• Late-stage pharmaceutical intermediates
• Generic API production pipelines
• High-purity research-grade building blocks for discovery chemistry

3. Protected Amino Acid Supply for Custom Fine Chemicals

Fine chemical manufacturers utilize the compound in the synthesis of advanced intermediates and specialty materials requiring precise stereochemistry and temporary protection. The tert-butoxycarbonyl protection provides robust stability for downstream functionalization, facilitating the introduction of complex side chains or labels prior to final deprotection. Strict documentation supports customer batch traceability and regulatory audits in specialty chemical sectors.

Industry compliance standards

• REACH Registration, Evaluation, Authorization and Restriction of Chemicals (EU)
• ISO 9001:2015 for process documentation and traceability
• Responsible Care® chemical handling protocols
• Custom client-specific raw material specifications (on request)

Typical usage ratio

• Applied at 1.05–1.15 molar equivalents in multistep syntheses
• Adjusted based on reactivity of label or side chain introduced
• Standard concentrations: 0.25–1.0 M in reaction solvents

Downstream process integration

• Introduced during derivatization and functionalization stages
• Protection group removed in final step by acidolysis using TFA or HCl
• Purified using preparative HPLC or crystallization as dictated by customer purity specifications
• Analytical data and batch traceability provided with each shipment

Final product types

• Specialty amino acid derivatives
• High-purity labels and affinity tags for biochemical assays
• Photoreactive building blocks
• Advanced intermediates for agrochemical R&D

4. Research-Grade Reagent for Biochemical Probe Synthesis

R&D laboratories and custom synthesis providers employ this compound as a backbone building block in the development of biochemical probes and labeled standards. Its stereo-defined structure and protective group enable attachment of detection tags or fluorophores under mild conditions, supporting intact probe synthesis for advanced biological assays and analytical method development.

Industry compliance standards

• ISO/IEC 17025 (Testing and Calibration Laboratories)
• OECD Principles of Good Laboratory Practice (GLP)
• US NIH Chemical Safety Standards
• Vendor-specific material traceability documentation

Typical usage ratio

• Used at 1:1 to 1:2 ratios with label- or fluorophore-activated reagents
• Pilot-scale synthesis (10 mg to 10 g) for method development
• Highly pure lots, typically ≥98.5% (HPLC), as required by analytical sensitivity

Downstream process integration

• Initial conjugation of protected amino component to activated probe moieties
• Subsequent Boc deprotection under mild acidic conditions to retain probe functionality
• Final purification via HPLC and structural confirmation by NMR/MS
• Documentation includes certificate of analysis for each lot

Final product types

• Biochemical assay probes
• Stable isotope-labeled amino acids
• Fluorogenic and chromogenic reagents for protein research
• Peptide-based imaging standards